Increxxa

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

тулатромицин

Available from:

Elanco GmbH

ATC code:

QJ01FA94

INN (International Name):

tulathromycin

Therapeutic group:

Cattle; Pigs; Sheep

Therapeutic area:

Антибактериални средства за системна употреба

Therapeutic indications:

Cattle: Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis susceptible to tulathromycin. Наличието на болестта в стадото трябва да бъде установено преди метафилактичното лечение. Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis susceptible to tulathromycin. Pigs: Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica susceptible to tulathromycin. Наличието на болестта в стадото трябва да бъде установено преди метафилактичното лечение. The product should only be used if pigs are expected to develop the disease within 2–3 days. Овца: лечение на ранните стадии на инфекцията pododermatitis (копытная гниене), свързани с вирулентным пилей dichelobacter nodosus, които изискват системно лечение.

Product summary:

Revision: 2

Authorization status:

упълномощен

Authorization date:

2020-09-16

Patient Information leaflet

                                36
B. ЛИСТОВКА
37
ЛИСТОВКА:
INCREXXA 100 MG/ML ИНЖЕКЦИОНЕН РАЗТВОР ЗА
ГОВЕДА, СВИНЕ И ОВЦЕ
1.
ИМЕ И ПОСТОЯНEН АДРЕС НА ПРИТЕЖАТЕЛЯ
НА ЛИЦЕНЗА ЗА УПОТРЕБА
И НА ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
Притежател на лиценза за употреба:
Elanco GmbH
Heinz-
Lohmann Str. 4
27472 Cuxhaven
Германия
Производител, отговорен за
освобождаване на партидата:
FAREVA Amboise
Zone
Industrielle,
29 route des Industries
37530 Pocé
-
sur
-
Cisse
Франция
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Increxxa 100 mg/ml инжекционен разтвор за
говеда, свине и овце
tulathromycin
3.
СЪДЪРЖАНИЕ НА АКТИВНАТА СУБСТАНЦИЯ И
ЕКСЦИПИЕНТИТЕ
Всеки ml съдържа:
АКТИВНА СУБСТАНЦИЯ:
Tulathromycin
100 mg
ЕКСЦИПИЕНТИ:
Monothioglycerol
5 mg
Прозрачен безцветен до слабо
жълтеникав инжекционен разтвор.
4.
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Говеда
Лечение и метафилаксия на
респираторни заболявания при говеда
(BRD), свързани с
_Mannheimia haemolytica_, _Pasteurella multocida_, _Histophilus somni
_и _Mycoplasma bovis_,
чувствителни към
tulathromycin
. Преди употребата
на продуктатрябва да бъде установено
наличие на заболяването
в групата.
Лечение на инфекциозен
кератоконюнктивит по говедата,
причинен от _Moraxella bovis_,
чувствителна към
tulathromycin
.
Свине
Лечение и метафилаксия на
респираторни заболявания при свинете
(SRD), с
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Increxxa 100 mg/ml инжекционен разтвор за
говеда, свине и овце
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всеки ml съдържа:
АКТИВНА СУБСТАНЦИЯ:
Tulathromycin
100 mg
ЕКСЦИПИЕНТИ:
Monothioglycerol
5 mg
За пълния списък на ексципиентите, виж
т.
6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Инжекционен разтвор.
Прозрачен, безцветен до слабо
жълтеникав разтвор.
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДОВЕ ЖИВОТНИ, ЗА КОИТО Е
ПРЕДНАЗНАЧЕН ВМП
Говеда, свине и овце.
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ, ОПРЕДЕЛЕНИ ЗА
ОТДЕЛНИТЕ ВИДОВЕ ЖИВОТНИ
Говеда
Лечение и метафилаксия на
респираторни заболявания при говеда
(BRD), свързани с
_Mannheimia haemolytica_, _Pasteurella multocida_, _Histophilus somni
_и _Mycoplasma bovis_,
чувствителни към tulathromycin. Преди
употребата
на продукта
трябва да бъде установено
наличие на заболяването
в групата.
Лечение на инфекциозен
кератоконюнктивит по говедата,
причинен от _Moraxella bovis_,
чувствителна към tulathromycin.
Свине
Лечение и метафилаксия на
респираторни заболявания при свинете
(SRD), свързани с
_Actinobacillus pleuropneumoniae_, _Pasteurella multocida_,
_Mycoplasma hyopneumoniae_, _Haemophilus _
_parasuis _и _Bordetella bronchiseptica_, чувствителни
към tulathromycin. Преди употребата
на
пр
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 08-12-2021
Public Assessment Report Public Assessment Report Spanish 11-10-2023
Patient Information leaflet Patient Information leaflet Czech 08-12-2021
Public Assessment Report Public Assessment Report Czech 11-10-2023
Patient Information leaflet Patient Information leaflet Danish 08-12-2021
Public Assessment Report Public Assessment Report Danish 11-10-2023
Patient Information leaflet Patient Information leaflet German 08-12-2021
Public Assessment Report Public Assessment Report German 11-10-2023
Patient Information leaflet Patient Information leaflet Estonian 08-12-2021
Public Assessment Report Public Assessment Report Estonian 11-10-2023
Patient Information leaflet Patient Information leaflet Greek 08-12-2021
Public Assessment Report Public Assessment Report Greek 11-10-2023
Patient Information leaflet Patient Information leaflet English 08-12-2021
Public Assessment Report Public Assessment Report English 17-12-2020
Patient Information leaflet Patient Information leaflet French 08-12-2021
Public Assessment Report Public Assessment Report French 11-10-2023
Patient Information leaflet Patient Information leaflet Italian 08-12-2021
Public Assessment Report Public Assessment Report Italian 11-10-2023
Patient Information leaflet Patient Information leaflet Latvian 08-12-2021
Public Assessment Report Public Assessment Report Latvian 11-10-2023
Patient Information leaflet Patient Information leaflet Lithuanian 08-12-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-12-2021
Public Assessment Report Public Assessment Report Lithuanian 11-10-2023
Patient Information leaflet Patient Information leaflet Hungarian 08-12-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 08-12-2021
Public Assessment Report Public Assessment Report Hungarian 11-10-2023
Patient Information leaflet Patient Information leaflet Maltese 08-12-2021
Public Assessment Report Public Assessment Report Maltese 11-10-2023
Patient Information leaflet Patient Information leaflet Dutch 08-12-2021
Public Assessment Report Public Assessment Report Dutch 11-10-2023
Patient Information leaflet Patient Information leaflet Polish 08-12-2021
Public Assessment Report Public Assessment Report Polish 11-10-2023
Patient Information leaflet Patient Information leaflet Portuguese 08-12-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 08-12-2021
Public Assessment Report Public Assessment Report Portuguese 11-10-2023
Patient Information leaflet Patient Information leaflet Romanian 08-12-2021
Public Assessment Report Public Assessment Report Romanian 11-10-2023
Patient Information leaflet Patient Information leaflet Slovak 08-12-2021
Public Assessment Report Public Assessment Report Slovak 11-10-2023
Patient Information leaflet Patient Information leaflet Slovenian 08-12-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 08-12-2021
Public Assessment Report Public Assessment Report Slovenian 11-10-2023
Patient Information leaflet Patient Information leaflet Finnish 08-12-2021
Public Assessment Report Public Assessment Report Finnish 11-10-2023
Patient Information leaflet Patient Information leaflet Swedish 08-12-2021
Public Assessment Report Public Assessment Report Swedish 11-10-2023
Patient Information leaflet Patient Information leaflet Norwegian 08-12-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 08-12-2021
Patient Information leaflet Patient Information leaflet Icelandic 08-12-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 08-12-2021
Patient Information leaflet Patient Information leaflet Croatian 08-12-2021
Public Assessment Report Public Assessment Report Croatian 11-10-2023

Search alerts related to this product

View documents history